Clinical trial
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered…
NCT00449527 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00449527 |
|---|---|
| Title | A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects |
| Official title | A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Daily Versus Weekly in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Actuations Twice Daily |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Budesonide/formoterol pMDI, Budesonide HFA pMDI |
| Enrollment | 123 |
| Start date | Mar 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Mar 20, 2007 |
| Last update posted | Jan 24, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: